SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, with its community demonstrating strong conviction and calling to 'hold' amidst current market volatility, anticipating a significant breakout. Many perceive it as 'digital silver' poised for substantial long-term growth, with discussions highlighting its foundational role and developments like LitVM and Omnichain features for earning yield.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, its motion sickness drug, marking the first new medication in this category in nearly 40 years. The community is highly optimistic, anticipating its significant potential to address GLP-1 associated nausea and sparking strong speculation of a major pharmaceutical buyout. With several additional pipeline catalysts on the horizon, many view the stock as deeply undervalued and poised for substantial future upside.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active and dedicated community, which passionately advocates for the "OG meme" narrative of Rage Comics. This committed base is consistently building out an ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into crypto while expressing strong conviction for significant long-term growth and widespread recognition, often positioning themselves against other meme coins for the top trending spot.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is actively discussed following the FDA's recent approval of FUROSCIX for pediatric use and new patents for its ReadyFlow Autoinjector, with a key PDUFA date for the autoinjector set for July 26, 2026. While many anticipate significant revenue growth from these developments and Afrezza's international expansion, a vocal segment of the community remains highly skeptical, citing past commercialization challenges and expressing strong dissatisfaction with current leadership.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is trending amidst active community discussion, fueled by recent visibility on Dextools and strong 'HODL' sentiment. Many investors are captivated by its potential for significant growth, often drawing parallels to $PEPE due to shared creator involvement, while others vocalize skepticism and concerns about its trajectory. The project also garnered attention for recent charitable donations to a cat adoption center, reinforcing its community-centric meme coin identity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biohaven (NYSE:BHVN) Trading 3.6% Higher - Here's What Happened

Biohaven (NYSE:BHVN) Shares Up 3.6% - What's Next...

Biohaven (NYSE:BHVN) Shares Gap Down - What's Next?

Biohaven (NYSE:BHVN) Shares Gap Down - Here's What Happened...

<ul class="summary-bullets"><li>Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half of 2026 will be the critical factor.</li><li>Citi emphasized that the study was expected to be difficult, and the company’s epilepsy program holds a higher probability of success.</li><li>H.C. Wainwright was unsurprised by the depression study outcome but advised caution leading into the seizures data readout.</li></ul>Biohaven Pharmaceuticals’ (BHVN) disappointing Phase II results for BHV-7000 in major depressive disorder have raised caution among Wall Street firms but have not completely shaken confidence in the company’s broader pipeline.The company announced on Wednesday that its Phase 2 study of BHV-7000 did not meet its primary endpoint.&nbsp;<h2 class="st-heading-2">Analyst Reactions&nbsp;&nbsp;</h2>William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects, according to TheFly.Analyst Myles Minter maintained a ‘Market Perform’ rating on the stock, citing that the company’s pivotal Phase III study for BHV-7000 in focal onset epilepsy in the first half of 2026 will be the critical factor in determining the drug’s effectiveness in an extended-release formulation.&nbsp;He added that the failure has minimal implications for&nbsp;Biohaven’s competitor, Xenon Pharmaceuticals' (XENE) depression trials.<h2 class="st-heading-2">Focus Shifts To 2026 Seizure Study</h2>According to Samantha Semenkow of Citi, who maintained a ‘Buy’ rating with a $14 price target, the market is more focused on the upcoming Phase III epilepsy results for BHV-7000 in 2026 than on the Phase II depression data.&nbsp;She emphasized that the earlier study was expected to be difficult, and the company’s epilepsy program holds a higher probability of success.&nbsp;H.C. Wainwright was unsurprised by the depression study outcome but advised caution leading into the seizures data readout. The firm maintained that the Phase II miss does not significantly impact expectations for Xenon Pharmaceuticals’ azetukalner Phase III trial in major depressive disorder.&nbsp;<h2 class="st-heading-2">What’s The Retail Mood On Stocktwits?</h2><a href="https://stocktwits.com/symbol/BHVN">Biohaven stock</a> traded over 14% lower in Friday’s premarket, and it was the top-trending equity ticker on StockTwits.&nbsp;However, retail sentiment around the stock remained in ‘bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:930/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_26_073329_png_a8c9a6c4f1.webp" alt="BHVN’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Dec. 26, 2025 | Source: Stocktwits" width="930" height="104"><figcaption>BHVN’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Dec. 26, 2025 | Source: Stocktwits</figcaption></figure>BHVN stock has declined by over 71% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-triples-in-2025-as-ai-memory-demand-supercharges-growth/cLeUIgNREwS">Micron Stock Triples In 2025 As AI Memory Demand Supercharges Growth: Retail Now Expects A Netflix-Like Super Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Biohaven’s Phase II Depression Trial Falls Short, But Analysts Downplay Impact – Wall Street Looks Ahead To Epilepsy Data

William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects. 

Equity

William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects. 


<ul class="summary-bullets"><li>The company also announced that it does not plan on additional psychiatric clinical trials and intends to prioritize its resources for other therapeutic areas including immunology, obesity and epilepsy in 2026.</li><li>BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder in March.</li><li>Last month, FDA refused to approve the company’s drug Vyglxia in the treatment of Spinocerebellar ataxia, sparking portfolio prioritization measures.</li></ul>Shares of Biohaven Ltd. (BHVN) slumped 17% after hours on Christmas eve after the company announced that its mid-stage proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder did not show a reduction of depressive symptoms.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html">said</a> that no reduction in depressive symptoms were observed in the trial over six weeks as compared with placebo though trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression.The drug was safe and well-tolerated with adverse events mostly mild and moderate in intensity and largely resolved spontaneously, the company said.The company also announced that it does not plan on additional psychiatric clinical trials and intends to prioritize its resources for other therapeutic areas including immunology, obesity and epilepsy in 2026.BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder in March. The company, however, is continuing the study of the drug in adult focal epilepsy.<h2 class="st-heading-2">Other Setbacks This Year</h2>The company’s setbacks this year are not limited to its psychiatry pipeline. Last month, the U.S. Food and Drug Administration <a href="https://stocktwits.com/news-articles/markets/equity/bhvn-stock-tumbles-pre-market-after-fda-refuses-approval-for-neurodegenerative-disorder-drug/cL2q0wsREGi">refused</a> to approve its drug Vyglxia in the treatment of Spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive loss of voluntary motor control and atrophy of the brain’s cerebellum and brainstem. In a letter, the FDA cited issues including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors in Biohaven’s drug studies.The company subsequently announced that it will focus on three late-stage, clinical programs with the greatest potential for value generation over the next year. It also initiated strategic portfolio and cost optimization across multiple programs to achieve an approximately 60% reduction in annual direct research and development spend.The company said last month that it may pause or delay non-priority programs to maintain its cash runway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHVN stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the negative update as “expected” and expressed optimism for the upcoming epilepsy trial. “Good things are to come here,” they wrote.<stembedurl>https://www.stocktwits.com/Dragonfire89/message/640093489</stembedurl>Yet another user sees the company’s investigational obesity drug being another interesting catalyst besides the epilepsy trial.<stembedurl>https://www.stocktwits.com/Reneejordan001/message/640092601</stembedurl><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html">BHVN stock</a> is down by 71% this year and by about 70% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-dismisses-ideas-of-spacex-echostar-merger-in-road-to-going-public/cLetcgcREvr">Elon Musk Dismisses Ideas Of SpaceX-Echostar Merger In Road To Going Public: ‘No Reason To Cut Corners’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts

The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 

Biohaven (NYSE:BHVN) Stock Price Down 13% - What's Next?

Biohaven (NYSE:BHVN) Stock Price Down 13% - Here's What Happened...

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive...

Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's  What You Should Know

The consensus price target hints at an 88.6% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know

Biohaven Ltd. (BHVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bellevue Group AG Raises Stock Holdings in Biohaven Ltd. $BHVN

Bellevue Group AG raised its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 37.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission...

Biohaven Ltd. $BHVN Position Trimmed by Redmile Group LLC

Redmile Group LLC lowered its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 15.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd